Clinical Observation Of Compound Yew Capsule On Maintenance In The Treatment Of Stage ?/? Lung Adenocarcinoma(Qi Deficiency And Phlegm Stasis Syndrome)

Objective:To observe the clinical efficacy of compound yew capsules in the treatment of patients with stage III/IV lung adenocarcinoma(qi deficiency and phlegm stasis syndrome).Methods:A prospective cohort study was conducted to include stage III/IV lung adenocarcinoma(qi deficiency and phlegm stasis syndrome)in the Department of Respiratory Oncology,Thoracic Surgery,Integrated Traditional Chinese and Western Medicine,or Outpatient Clinic of Gansu Provincial Cancer Hospital from September 1,2017 to December31,2018.64 patients were treated with compound yew capsule as the exposure factor and divided into treatment group and control group.The treatment group was given compound yew capsules(3 capsules orally 3 times a day)for maintenance treatment and best supportive care(BSC),and the control group received the best supportive treatment.21 days was a cycle,and every two cycles were followed up until the disease progressed or died.The patient's progression-free survival(PFS)was counted,and the disease control rate(DCR),arnofsky score,quality of life score,improvement rate of TCM clinical symptom and other efficacy indicators were evaluated.Results:(1)Progression-free survival(PFS): the median PFS of the treatment group and the control group were 4.2 months and 2.9 months,respectively.Kaplan-meier survival analysis method was used,and log-rank test showed that P=0.011,indicating a statistically significant difference.(2)Disease control rate(DCR): the disease control rates of the treatment group and the control group were 80.6% and 56.7%,respectively,P=0.045,and the difference was statistically significant.(3)Karnofsky score: the improvement rates of KPS scores in the treatment group and the control group were 38.7% and 16.7%,respectively.By rank sum test,P=0.010,the difference was statistically significant.(4)Improvement rate of TCM symptoms:the improvement rates of TCM symptoms in the treatment group and the control group were38.7% and 13.3%,respectively.The rank sum test showed that P=0.029,and the difference was statistically significant.(5)Quality of life: the quality of life of the patients was evaluated by the FACT that L4.0 quality of life score scale.The results showed that,After 4 cycles of treatment,in addition to the social/family status,the scores of the other 4 areas were significantly higher in the treatment group,P<0.05,which was statistically significant.In thecontrol group,except for the physiological status,the scores of the other 4 fields were compared.There was an increase,but P>0.05,the difference was not statistically significant.(6)Adverse reactions: 1 patient in the treatment group developed nausea,which was relieved after untreated for 20 min.One patient showed grade I leukopenia,which returned to normal after oral treatment of Diyushengbai tablet.Conclusions: Compound taxus capsule maintenance treatment of of patients with stage III/IV lung adenocarcinoma(qi deficiency and phlegm stasis syndrome)can prolong the progression-free survival time,improve the quality of life,and the security is good,no obvious toxicity was observed.